Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Apr
1
2020
Gifting Goods & Services to the U.S. Government in the Wake of the Coronavirus Outbreak Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2020
Clearing the Air: FinCEN Guidance May Help Banks Find Their Way in the Field of Hemp Financing Sheppard, Mullin, Richter & Hampton LLP
Apr
30
2024
FDA Makes Good on Its Promise to Regulate Laboratory-Developed Tests Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2021
FDA’s Action Plan for Artificial Intelligence: Highlights and Insights for Developers Sheppard, Mullin, Richter & Hampton LLP
Mar
8
2021
California Legislative Update: Employment-Related Bills on the Horizon Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2010
Proposition 23's Failure Means Full Speed Ahead on AB 32 Sheppard, Mullin, Richter & Hampton LLP
Feb
9
2018
Temporal Proximity Is Not Enough: Third Circuit Nixes FCA/Anti-Kickback Suit For Failure To Link Alleged Scheme to Claims Sheppard, Mullin, Richter & Hampton LLP
Jul
30
2013
Food and Drug Administration (“FDA”) Draft Guidance For Industry On Pre-Launch Activities Importation Requests: Dead On Arrival? Sheppard, Mullin, Richter & Hampton LLP
Sep
22
2021
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2013
Unusual Circumstances: California Supreme Court Upholds Limited Use of Future Conditions Baseline Under California Environmental Quality Act (CEQA) Sheppard, Mullin, Richter & Hampton LLP
Nov
22
2021
FDA Joins Other Regulators in Focus on AI and Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2019
HIMMS19 Conference – Blockchain Symposium Recap Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2019
OH SNAP! Supreme Court to Take on Meaning of Key FOIA Exemption Sheppard, Mullin, Richter & Hampton LLP
Nov
11
2014
Amgen/Sandoz Disputes Will Clarify BPCIA (Biologics Price Competition and Innovation Act) Issues Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2014
Dole Defeats “All Natural Claims” for Sweet Victory Sheppard, Mullin, Richter & Hampton LLP
Sep
15
2022
California Expands FEHA to Include Off The Job Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
Oct
13
2022
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies Sheppard, Mullin, Richter & Hampton LLP
Mar
4
2015
Ascertainability Saps Plaintiffs’ Energy in Dietary Supplement Class Action Sheppard, Mullin, Richter & Hampton LLP
Feb
22
2023
CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2023
On the Horizon: Broad Employment Protections for Marijuana Users in the District of Columbia Sheppard, Mullin, Richter & Hampton LLP
Jun
16
2023
FDA Issues First Untitled Letter of the Year to Xeris Pharmaceuticals Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2023
Commercial Cannabis Permit Program and Overlay District Statutorily Exempt Under CEQA Guideline Section 15183 Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2023
Overview of Recent Anti-Corruption Enforcement Actions in the Pharmaceutical Industry in China Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2020
Key Health Care Provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) Sheppard, Mullin, Richter & Hampton LLP
Apr
9
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2020
As America Prepares to Return to Work, EEOC Approves Testing Employees for COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Jul
9
2020
COVID-19’s Continued Impacts on Cannabis Operators Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins